Beta%2525252525252525252525252520blockers

# Beta-blockers ## Overview Beta-adrenergic receptor antagonists lower heart rate, myocardial contractility, and blood pressure by blocking catecholamine binding to beta-1 and/or beta-2 receptors. They are categorized as non-selective (e.g., propranolol), cardioselective (beta-1 specific, e.g., metoprolol), or vasodilatory (e.g., carvedilol, nebivolol). ## Primary Indications * Hypertension * Chronic heart failure (HFrEF) * Post-myocardial infarction (MI) * Atrial fibrillation/flutter (rate control) * Angina pectoris * Essential tremor (propranolol) * Migraine prophylaxis (propranolol/timolol) ## Adult Dosing * **Metoprolol Succinate (ER):** Start 25–50 mg daily; titrate to max 200 mg daily. * **Metoprolol Tartrate (IR):** 25–100 mg twice daily. * **Carvedilol:** Start 3.125–6.25 mg twice daily; titrate to max 25–50 mg twice daily (HF). * **Atenolol:** 25–100 mg daily. * **Bisoprolol:** 2.5–10 mg daily. * *Note:* Dosing varies by indication; titration for HF requires slow, stepwise increments. ## Pediatric Dosing Dosing is highly indication-specific and weight-based. * **Propranolol (Hypertension):** 0.5–1 mg/kg/day divided twice daily (Max 8 mg/kg/day). * **Atenolol (Hypertension):** 0.5–1 mg/kg/day (Max 2 mg/kg/day). * *Caution:* Pediatric dosing often requires specialized references (e.g., Neofax or Harriet Lane) as standard adult guidelines do not apply. ## Dose Adjustments * **Renal Impairment:** Atenolol and bisoprolol require dose reductions (renal clearance). Lipophilic agents (metoprolol, propranolol) are hepatically cleared and generally require no dose adjustment. * **Hepatic Impairment:** Reduce doses for propranolol and carvedilol due to extensive first-pass metabolism. ## Contraindications * Second- or third-degree AV block (without a pacemaker). * Severe bradycardia (typically <50 bpm). * Decompensated heart failure (unless stable). * Cardiogenic shock. * Severe reactive airway disease (bronchospastic asthma—use selective agents with caution only if no alternative). ## Adverse Effects * Bradycardia and hypotension. * Fatigue and exercise intolerance. * Masking of hypoglycemia symptoms (tachycardia/tremor). * Sexual dysfunction. * Cold extremities (Raynaud-like symptoms). * Wheezing (non-selective agents). ## Key Drug Interactions * **CYP2D6 Inhibitors:** (e.g., fluoxetine, paroxetine) can significantly increase levels of metoprolol or carvedilol. * **Non-DHP CCBs:** (e.g., diltiazem, verapamil) risk of synergistic AV nodal blockade, bradycardia, and heart failure. * **Digoxin:** Additive bradycardia. * **Insulin/Sulfonylureas:** Masking of hypoglycemic warning signs. ## Monitoring * Heart rate and blood pressure (pre-dose and during titration). * Blood glucose (in diabetic patients). * Signs of peripheral edema or worsening dyspnea (HF patients). * ECG for PR interval prolongation. ## Clinical Pearls * **Never discontinue abruptly:** Sudden withdrawal can trigger rebound hypertension, tachycardia, or myocardial ischemia; taper over 1–2 weeks. * **Cardioselectivity:** Selectivity is lost at higher doses; "selective" agents (metoprolol/bisoprolol) should still be used with extreme caution in severe asthma. * **Heart Failure titration:** Patients must be clinically stable before initiating or increasing beta-blocker therapy to avoid acute decompensation. *** *Educational Disclaimer: This information is for educational purposes only. Clinical practice protocols vary. Always verify current prescribing information, contraindications, and patient-specific dosing in reputable databases like Lexicomp, Micromedex, or official product labeling before prescribing or dispensing.*